BACKGROUND: While there is growing demand for information about comparative effectiveness (CE), there is substantial debate about whether and when observational studies have sufficient quality to support decision making.
RESULTS: Taken as a whole, the scale had better NPV than PPV, for both data and methods. The most consistent predictor of quality relates to the validity of the primary outcomes measurement for the study purpose. Other consistent markers of quality relate to using concurrent comparators, minimizing the effects of bias by prudent choice of covariates, and using sensitivity analysis to test robustness of results. Concordance of expert opinion on the quality of the rated articles was 52%; most checklist items performed better.
CONCLUSIONS: The 11-item GRACE checklist provides guidance to help determine which observational studies of CE have used strong scientific methods and good data that are fit for purpose and merit consideration for decision making. The checklist contains a parsimonious set of elements that can be objectively assessed in published studies, and user testing shows that it can be successfully applied to studies of drugs, medical devices, and clinical and surgical interventions. Although no scoring is provided, study reports that rate relatively well across checklist items merit in-depth examination to understand applicability, effect size, and likelihood of residual bias.
The current testing and validation efforts did not achieve clear discrimination between studies fit for purpose and those not, but we have identified a critical, though remediable, limitation in our approach. Not specifying a specific granular decision for evaluation, or not identifying a single study objective in reports that included more than one, left reviewers with too broad an assessment challenge. We believe that future efforts will be more successful if reviewers are asked to focus on a specific objective or question.
• While there is growing demand for information about comparative effectiveness (CE), there is little understanding about when noninterventional studies are good enough for decision support.
• Several expert reports have been issued listing criteria that are believed to be important in determining the quality of observational CE studies, yet there have been no systematic, published evaluations of whether or how such criteria actually perform.
What is already known about this subject
• We developed the GRACE checklist, an objective 11-item checklist about the key attributes of high-quality noninterventional CE studies, a checklist that evaluates data and methods, but not motives, conflicts of interest, or interpretation. We then conducted several validation efforts using a large number of raters with diverse training and experience to determine how those individual elements performed when applied to expert opinions on quality.
• This testing revealed that the most consistent predictors of quality relate to the validity of the primary outcomes for the study purpose.
• Other relatively consistent predictors of quality were related to use of concurrent comparators, whether important covariates were recorded and accounted for, and whether sensitivity analyses were shown to support robustness of the conclusion.
ReseArch for Comparative Effectiveness (GRACE) checklist, which has been tested for its clarity and ability to distinguish sufficient quality work according to study purpose. This article describes the development and approaches to validation of an item checklist that can be used to identify observational CE studies sufficiently rigorous in design and execution for decision support. We focused on relatively objective criteria that can be assessed through review of published study reports.
■■ Methods
We drafted the initial checklist from the GRACE principles for observational CE studies, developed in collaboration with the International Society of Pharmacoepidemiolgy. 3 The checklist was fine-tuned for content validity by consultation with experts and extensive literature review, including reports from the Agency for Healthcare Research and Quality on rating the strength of scientific research findings, [16] [17] [18] the Grading of Recommendations Assessment, Development and Evaluation process, 19, 20 reporting guidelines, and other tools for assessing clinical and observational study quality. [21] [22] [23] [24] [25] [26] Senior scientists from academia, industry, and payers were also consulted about item selection and scoring, some of whom also served as expert raters. User instructions and response levels for the refined list of questions were developed by the authors.
Checklist testers were recruited via emails and personal requests and also through the website www.graceprinciples.org. Volunteers (N = 113) from North and South America, Europe, Asia, and Africa conducted a total of 280 assessments of 88 articles. Testers included clinicians, academics, and representatives from industry, health departments, and other nonprofit agencies. They reported a wide range of training and experience with epidemiologic and statistical methods. The construct validity of the checklist was assessed using a variation on the "Extreme Groups" approach 27 by applying the checklist to 3 "validation sets" of observational CE research studies. We compared checklist item responses 3 different ways with external quality ratings, using published articles of observational CE or safety studies: (a) Systematic Review-quality assessment from a published systematic review; (b) Single Expert Review-quality assessment made according to the solicited "expert opinion" of a senior researcher; and (c) Concordant Expert Review-quality assessments from 2 experts for which there was concordance. The first version of the checklist was used for the Systematic Review validation test. It was then fine tuned for subsequent testing in the Single Expert and Concordant Expert Reviews.
In the first test, a sample of articles was drawn from published systematic reviews that listed the articles considered for inclusion, along with their quality assessments (articles listed in Appendix, available in online article). [28] [29] [30] [31] [32] [33] Articles were considered "good" if they met quality criteria required for inclusion D eveloping a sustainable health system requires health care that is guided by reliable information about which medical diagnostics and treatments work best, for whom, and in what situations. 1 To meet the diverse needs of clinicians, policy makers, and those who decide about formularies, the full range of comparative effectiveness (CE) studies-randomized controlled trials, observational research (also referred to as noninterventional research since treatments are not assigned by protocol), and meta-analyses-are needed. Observational studies are particularly useful because they often provide information about diverse populations, practitioners, and settings in a timely and cost-effective manner.
Recent calls for using the full range of high-quality CE research to inform decisions about medical diagnostics and interventions have brought forth a spate of consensus offerings about recognizing quality in observational CE studies and meta-analysis. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These papers have face validity and largely appear reasonable, but there is little, if any, evidence that any of these recommendations can actually distinguish studies of sufficient quality to merit serious evaluation for a particular clinical or payment decision. For example, some guidelines address potential conflicts of interest by calling for full disclosure, a standard journal practice that relies on individual assessment of potential conflicts. Some insist that, like clinical trials, only hypotheses that were specified in advance of collecting any data have validity. Others omit the criterion about prespecified hypotheses, instead giving more weight to the value of descriptive data for filling gaps and shaping subsequent research. One very practical, high-level description of good practice, published in this journal by Willke and Mullins in 2011, 9 focused on good research practices for the conduct and reporting of CE research using real-world data with nonrandom assignment of treatments. They offer "Ten Commandments for improving the systematic use of principles that are aimed at achieving the goals of developing credible and germane CE research studies using real world data." 9 We support that goal and have attempted to further it with the development of the Good • On the whole, GRACE checklist items performed better than opinions from individual experts and concurrent expert opinions. Nonetheless, the checklist would benefit from further validation efforts, including directing reviewers to address a specific objective for each evaluation, finding additional validation test sets to evaluate the robustness of the checklist, and conducting more multivariate analyses to determine whether any combinations or sequences of responses can improve the ability of the checklist to discriminate studies of reasonably strong quality for the purpose at hand.
What this study adds (continued)
www . in the systematic review and were considered to be of insufficient quality if they were excluded from the review. For testing, authorship was blinded by redaction to avoid biasing quality determinations, and testers were asked not to try to identify the authors through other means. Of 48 articles, 21 were considered "good" and 27 "not good enough"; 172 completed assessments were received from 58 testers, with each article receiving an average of 4 reviews (range, 1-9 reviews).
In the second set of tests (Expert Reviews), the experts received directions explicit to the use of the articles for "decision support" and were asked to decide whether each observational CE study was of sufficient quality to support a formulary decision. Ten senior academic and industry experts were asked to rate 4 or more published observational CE articles as either "sufficient quality to be used to support a formulary decision" or "sufficiently flawed to make interpretation unreliable." The Single Expert Review consisted of 40 articles: 23 that experts rated as sufficient and 17 that were rated as too flawed to be useful for this purpose.
For the third set of tests (Concordant Expert Reviews), 5 experts reviewed 23 of the 40 articles to assess concordance. The articles used for testing are listed in Appendix B (available in online article), and the 14 experts are listed in the acknowledgements (10 participated in the Single Expert Review; 1 of those 10 plus 4 others reviewed articles in the Concordant Expert Review). Fifty-five additional volunteer testers applied the checklist to 2 articles each in this validation, completing a total of 108 assessments, with each article receiving an average of 2.7 reviews (range, 2-7 reviews). One item was dropped after the first round of testing when we learned that none of the articles reviewed stated whether the hypotheses had been specified before the study began. Checklist items were also revised before subsequent testing to improve clarity. In addition, user instructions were clarified after review by 2 authors (Dreyer and Velentgas) to accommodate better evaluation of studies of medical devices and procedures as well as drugs.
Question response levels in the checklist were mapped to dichotomized categories of "sufficient (good enough for decision support)" or "insufficient." Responses that indicated "not enough information in article" were treated as "insufficient," since this lack of information could be viewed as a negative aspect of study quality. Responses of "not applicable" were classified as "sufficient" so that an article would not be rated negatively if a specific question item was not relevant to its objective. Blank responses were treated as missing values. Positive and negative predictive values were estimated for each checklist item to describe how well a reviewer's assessments, using the checklist, compared with an expert's assessment of study quality (in this case, the best available "gold standard" for assessment of study quality). For each article, a single review from a tester, randomly selected from the multiple reviews per article, was compared with the "gold standard." This comparison was done twice to ensure that results were not highly dependent on the random subset selected. Results from both analysis subsets are presented in the Results section. All analyses presented were conducted using SAS 9.2 (Cary, NC).
■■ Results
The GRACE checklist, as modified through this testing process, is shown in Table 1 . Questions are grouped into those relating to data and methods, and the guide to scoring reflects clarifications and revisions based on feedback from raters and journal reviewers. Table 2 presents predictive values, comparing testers' assessments of checklist items to experts' overall quality assessments. This comparison was done for 2 sample reviews for each of the 3 validations (6 samples total), stratified by positive predictive value (PPV) and negative predictive value (NPV).
Taken as a whole, the checklist showed better NPV than PPV, with 31 individual items scoring at least 0.67 for NPV versus only 20 items for PPV. A similar trend was evident when looking at both data and methods questions; 20 versus 11 data items scored ≥ 0.67, and 11 versus 9 methods items NPV and PPV, respectively. Each of the 11 items showed some potential for NPV (using the ≥ 0.67 criterion), and 9 of the 11 questions also showed some potential for their PPV. The single question that most consistently showed strong NPV and PPV addressed the validity of the primary outcomes (D4, Table 1 ). For PPV, the other question that most consistently scored relatively high was whether a sensitivity analysis had been conducted (M5, Table 1 ). The 2 most frequently identifiable predictors of negative quality were the absence of a concurrent comparator group (M2 , Table 1 ) and the lack of adequate details on outcomes (D2, Table 1), followed by not using appropriate clinical outcomes where applicable (D3 and D4, Table 1 ).
■■ Discussion
The GRACE checklist was designed as an initial evaluation tool to broadly screen the quality of observational CE studies to select those worth in-depth consideration. We focused on 11 checklist elements, 6 relating to data and 5 relating to methods. Using an arbitrarily selected cut-point of 0.67 to indicate relatively strong predictive value, checklist questions about data generally showed better predictive value than questions about methods. Two of the most consistent predictors of quality appropriate for purpose related to (1) valid outcomes and (2) use of concurrent comparators, both factors with important design, analytic, and budgetary ramifications. Our small test of concordance among expert reviewers revealed an unsettling lack of agreement about what "good" looks like through consensus. There was agreement on quality only for 12 of 23 articles (52%) rated by 2 experts-hardly an endorsement for pure reliance on expert assessments.
Components
Scoring as Fit for Purpose: Sufficient (+), Insufficient (-) Data D1. Were treatment and/or important details of treatment exposure adequately recorded for the study purpose in the data sources? Note: not all details of treatment are required for all research questions.
(+) Yes, reasonably necessary information to determine treatment or intervention was adequately recorded for study purposes (e.g., for drugs, sufficient detail on dose, days supplied, route or other important data; for vaccines, batch, dose, route, and site of administration, etc.; for devices, type of device, placement, surgical procedure used, serial number, etc.) (-) No, data source clearly deficient or not enough information in article. D2. Were the primary outcomes adequately recorded for the study purpose (e.g., available in sufficient detail through data sources)?
(+) Yes, information to ascertain outcomes was adequately recorded in the data sources (e.g., if clinical outcomes were ascertained using ICD-9-CM diagnosis codes in an administrative database, the level of sensitivity and specificity captured by the codes was sufficient for assessing the outcome of interest). (-) No, data source clearly deficient (e.g., the codes captured a range of conditions that was too broad or narrow, and supplementary information such as that from medical charts was not available, or not enough information in article). D3. Was the primary clinical outcome measured objectively rather than subject to clinical judgment (e.g., opinion about whether the patient's condition has improved)?
(+) Yes, clinical outcome was measured objectively (e.g., hospitalization, mortality). (+) Not applicable (primary outcome not clinical, such as PROs). (-) No (e.g., clinical opinion about whether patient's condition improved, or not enough information in article). D4. Were primary outcomes validated, adjudicated, or otherwise known to be valid in a similar population? (+) Yes, outcomes were validated, adjudicated, or based on medical chart abstractions with clear definitions (e.g., a validated instrument was used to assess PROs [such as SF-12 Health Survey]; a clinical diagnosis via ICD-9-CM code was used, with formal medical record adjudication by committee to confirm diagnosis or other procedures to achieve reasonable sensitivity and specificity; billing data were used to assess health resource utilization, etc). (+) Yes, data were collected during the same time period as the treatment group ("concurrent"), or historical comparators were used with reasonable justification (e.g., when it was impossible for researchers to identify current users of older treatments or when a concurrent comparison group was not valid, as when uptake of new product is so rapid that concurrent comparators differ greatly on factors related to the outcome). (-) No, historical comparators used without being scientifically justifiable, or not enough information in article. M3. Were important confounding and effect modifying variables taken into account in the design and/or analysis? Appropriate methods to take these variables into account may include restriction, stratification, interaction terms, multivariate analysis, propensity score matching, instrumental variables, or other approaches.
(+) Yes, most if not all important covariates that would be likely to change the effect estimate substantially were accounted for (e.g., measures of medication dose and duration). (-) No, some important covariates were available for analysis but not analyzed appropriately, or at least 1 important covariate was not measured, or not enough information in article. M4. Is the classification of exposed and unexposed person-time free of "immortal time bias"? (Immortal time in epidemiology refers to a period of cohort follow-up time during which death, or an outcome that determines end of follow-up, cannot occur.) 
Limitations
Although the current testing and validation efforts did not achieve clear discrimination between studies fit for purpose and those not, we identified a critical but remediable limitation in our approach. By not specifying a specific granular decision for evaluation (e.g., "Is this study of sufficient quality to compare the relative safety of two drugs?") or identifying a single study objective in situations where reports included more than 
Predictive Values by Item for All Validation Test Sets
employed consensus methods, which have face validity, but without evaluation of reliability and discriminant validity, it is uncertain how they would perform in a similar exercise.
■■ Conclusions
Taken as a whole, the GRACE checklist can help as a screening tool to eliminate studies that do not meet the baseline quality requirements for observational studies of comparative effectiveness. We recommend that the GRACE checklist be used as a "first pass" to evaluate how a given study measures against each of the checklist items when applied to a specific study question. Those studies that appear to be fairly sound in design and methods in the context of the study purpose should be examined more closely to evaluate the comparability of the study population to the target population of interest, the appropriateness of the specific medical interventions and comparators for use in the target population, and the likelihood of intractable bias and relevance of the outcomes to patients and health care providers. Studies should also receive further review in the context of available evidence regarding relative risks and benefits and the required threshold for decision support, ideally by those with methodological and content area knowledge.
Despite the drawbacks in the GRACE checklist and other tools, having an agreed upon set of assessment elements, checklists, or score cards is critical for the maturation of the field. Substantial resources will be expended on studies of real-world effectiveness, and if the rigor of these observational assessments cannot be ascertained, then the impact of those studies will be suboptimal. Similarly, agreement on key elements of quality will ensure that budgets are appropriately directed toward those key elements of quality. Given the centrality of this task and the lessons learned from these extensive efforts at validation and user testing, we are optimistic about the potential for improved assessments. We believe that the necessary tools can be produced, enabling diverse types of assessments by people with a wide range of experience and training.
1 objective (e.g., "Does this study demonstrate greater compliance with once per week vs. daily therapy?"), reviewers were left with too broad an assessment. We believe that future efforts will be more successful if reviewers are asked to focus on a specific objective or question.
The GRACE checklist also does not provide a single quantitative summary score or "pass/fail" result. Our experts counseled that a summary result from the checklist would not be broadly reflective of the numerous considerations that go into assessing the quality of a given study and whether it is sufficient for a specific purpose. Related efforts have concluded that a pass/fail score would require much more tailoring of a checklist to address specific issues and contexts, such as the types of decisions faced by pharmacy, payer, and other health care constituencies and specific therapeutic areas. Nonetheless, we conducted some preliminary analyses using CART software (Salford Systems, San Diego, CA) to create regression trees. Unfortunately, no consistently high-performing combination of checklist items was identified that would correctly classify studies as good or of insufficient quality. Since then, the checklist instructions and scoring have been improved through testing, and additional analyses may be more fruitful. In addition, by addressing the limitation discussed above and specifying the purpose of the review, an overall quantitative assessment may be feasible.
In addition, the GRACE checklist would benefit from further development using different validation sets, improving instructions to raters, and further analysis of results to see if any combination or sequence of item responses has particularly high predictive validity. The articles we selected from systematic reviews, for example, reflected publications that had been examined thoroughly and vetted by a group of experts. However, not all of these articles reflected use of modern methods, particularly as they relate to design and analysis of noninterventional CE studies, because by the time a systematic review had been conducted and published, the articles used were dated. Finding well-accepted standards against which to test checklist items to further refine the distinguishing aspects of quality remains an open question. [34] [35] [36] When considering the GRACE checklist's limitations, it is important to keep in mind what alternative tools exist and their utility for this purpose. The well-recognized STROBE and CONSORT guidelines address how to report study results and were not designed to assess study quality; therefore, they would not be sufficient substitutes. 37 Tools not developed specifically for pharmacoepidemiology are unlikely to include the relevant elements critical for description, assessment of CE, and likelihood of bias.
38 Perhaps most importantly, to our knowledge, none of the other assessment guidelines or standards have been subjected to much, if any, testing. The developers of those tools 9. Willke RJ, Mullins CD. "Ten Commandments" for conducting comparative effectiveness research using "real-world data." J Manag Care Pharm. 2011;17 (9 Suppl A):S10-S15. 
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